CBAY
Cymabay Therapeutics Inc
Halal Rating :
Last Price
$32.48
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and providing therapies to treat liver and other chronic diseases with high unmet medical need. Their lead product candidate is seladelpar, which is in development for the treatment of patients with primary biliary cholangitis (PBC), a rare and chronic autoimmune liver disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2023 | $57000.0 | $47.64m | - | $5.08m | 0.00% | 10.67% |
| June 30, 2023 | $31.02m | $35.73m | - | $4.62m | 0.00% | 12.92% |
Company Impact
Help us evaluate Cymabay Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.